Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2024-09-27 DOI:10.1111/apt.18278

Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R. Brunetto, Wan-Long Chuang, Harry L. A. Janssen, Scott K. Fung, Namiki Izumi, Maciej S. Jablkowski, Dzhamal Abdurakhmanov, Frida Abramov, Hongyuan Wang, Irina Botros, Leland J. Yee, Roberto Mateo, John F. Flaherty, Anu Osinusi, Calvin Q. Pan, X. Shalimar, Wai-Kay Seto, Edward J. Gane

引用次数: 0

Abstract

In two phase 3 studies, tenofovir alafenamide (TAF) showed non-inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB).

Abstract Image

查看原文本刊更多论文

替诺福韦-阿拉非那胺治疗慢性乙型肝炎病毒感染的八年疗效和安全性：两项随机三期试验的最终结果

在两项三期研究中，替诺福韦-阿拉非那胺（TAF）与富马酸替诺福韦二吡呋酯（TDF）相比，疗效并不逊色，而且对慢性乙型肝炎（CHB）患者的肾脏和骨骼安全性更为有利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.